Research ExplorerPublicationsLifeTime and improving European healthcare through cell-base...

LifeTime and improving European healthcare through cell-based interceptive medicine

Standard

LifeTime and improving European healthcare through cell-based interceptive medicine. / Rajewsky, Nikolaus; Almouzni, Geneviève; Gorski, Stanislaw A; Aerts, Stein; Amit, Ido; Bertero, Michela G; Bock, Christoph; Bredenoord, Annelien L; Cavalli, Giacomo; Chiocca, Susanna; Clevers, Hans; De Strooper, Bart; Eggert, Angelika; Ellenberg, Jan; Fernández, Xosé M; Figlerowicz, Marek; Gasser, Susan M; Hubner, Norbert; Kjems, Jørgen; Knoblich, Jürgen A; Krabbe, Grietje; Lichter, Peter; Linnarsson, Sten; Marine, Jean-Christophe; Marioni, John C; Marti-Renom, Marc A; Netea, Mihai G; Nickel, Dörthe; Nollmann, Marcelo; Novak, Halina R; Parkinson, Helen; Piccolo, Stefano; Pinheiro, Inês; Pombo, Ana; Popp, Christian; Reik, Wolf; Roman-Roman, Sergio; Rosenstiel, Philip; Schultze, Joachim L; Stegle, Oliver; Tanay, Amos; Testa, Giuseppe; Thanos, Dimitris; Theis, Fabian J; Torres-Padilla, Maria-Elena; Valencia, Alfonso; Vallot, Céline; van Oudenaarden, Alexander; Vidal, Marie; Voet, Thierry; LifeTime Community Working Groups.

In: NATURE, Vol. 587, No. 7834, 11.2020, p. 377-386.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rajewsky, N, Almouzni, G, Gorski, SA, Aerts, S, Amit, I, Bertero, MG, Bock, C, Bredenoord, AL, Cavalli, G, Chiocca, S, Clevers, H, De Strooper, B, Eggert, A, Ellenberg, J, Fernández, XM, Figlerowicz, M, Gasser, SM, Hubner, N, Kjems, J, Knoblich, JA, Krabbe, G, Lichter, P, Linnarsson, S, Marine, J-C, Marioni, JC, Marti-Renom, MA, Netea, MG, Nickel, D, Nollmann, M, Novak, HR, Parkinson, H, Piccolo, S, Pinheiro, I, Pombo, A, Popp, C, Reik, W, Roman-Roman, S, Rosenstiel, P, Schultze, JL, Stegle, O, Tanay, A, Testa, G, Thanos, D, Theis, FJ, Torres-Padilla, M-E, Valencia, A, Vallot, C, van Oudenaarden, A, Vidal, M, Voet, T & LifeTime Community Working Groups 2020, 'LifeTime and improving European healthcare through cell-based interceptive medicine', NATURE, vol. 587, no. 7834, pp. 377-386. https://doi.org/10.1038/s41586-020-2715-9

APA

Rajewsky, N., Almouzni, G., Gorski, S. A., Aerts, S., Amit, I., Bertero, M. G., Bock, C., Bredenoord, A. L., Cavalli, G., Chiocca, S., Clevers, H., De Strooper, B., Eggert, A., Ellenberg, J., Fernández, X. M., Figlerowicz, M., Gasser, S. M., Hubner, N., Kjems, J., ... LifeTime Community Working Groups (2020). LifeTime and improving European healthcare through cell-based interceptive medicine. NATURE, 587(7834), 377-386. https://doi.org/10.1038/s41586-020-2715-9

Vancouver

Rajewsky N, Almouzni G, Gorski SA, Aerts S, Amit I, Bertero MG et al. LifeTime and improving European healthcare through cell-based interceptive medicine. NATURE. 2020 Nov;587(7834):377-386. https://doi.org/10.1038/s41586-020-2715-9

Bibtex

@article{169cbc452ece44598677867853f722b9,
title = "LifeTime and improving European healthcare through cell-based interceptive medicine",
abstract = "Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.",
keywords = "Artificial Intelligence, Cell- and Tissue-Based Therapy, Delivery of Health Care/ethics, Early Diagnosis, Education, Medical, Europe, Female, Health, Humans, Legislation, Medical, Male, Medicine/methods, Pathology, Single-Cell Analysis",
author = "Nikolaus Rajewsky and Genevi{\`e}ve Almouzni and Gorski, {Stanislaw A} and Stein Aerts and Ido Amit and Bertero, {Michela G} and Christoph Bock and Bredenoord, {Annelien L} and Giacomo Cavalli and Susanna Chiocca and Hans Clevers and {De Strooper}, Bart and Angelika Eggert and Jan Ellenberg and Fern{\'a}ndez, {Xos{\'e} M} and Marek Figlerowicz and Gasser, {Susan M} and Norbert Hubner and J{\o}rgen Kjems and Knoblich, {J{\"u}rgen A} and Grietje Krabbe and Peter Lichter and Sten Linnarsson and Jean-Christophe Marine and Marioni, {John C} and Marti-Renom, {Marc A} and Netea, {Mihai G} and D{\"o}rthe Nickel and Marcelo Nollmann and Novak, {Halina R} and Helen Parkinson and Stefano Piccolo and In{\^e}s Pinheiro and Ana Pombo and Christian Popp and Wolf Reik and Sergio Roman-Roman and Philip Rosenstiel and Schultze, {Joachim L} and Oliver Stegle and Amos Tanay and Giuseppe Testa and Dimitris Thanos and Theis, {Fabian J} and Maria-Elena Torres-Padilla and Alfonso Valencia and C{\'e}line Vallot and {van Oudenaarden}, Alexander and Marie Vidal and Thierry Voet and {LifeTime Community Working Groups} and Paulus Kirchhof",
year = "2020",
month = nov,
doi = "10.1038/s41586-020-2715-9",
language = "English",
volume = "587",
pages = "377--386",
journal = "NATURE",
issn = "0028-0836",
publisher = "NATURE PUBLISHING GROUP",
number = "7834",

}

RIS

TY - JOUR

T1 - LifeTime and improving European healthcare through cell-based interceptive medicine

AU - Rajewsky, Nikolaus

AU - Almouzni, Geneviève

AU - Gorski, Stanislaw A

AU - Aerts, Stein

AU - Amit, Ido

AU - Bertero, Michela G

AU - Bock, Christoph

AU - Bredenoord, Annelien L

AU - Cavalli, Giacomo

AU - Chiocca, Susanna

AU - Clevers, Hans

AU - De Strooper, Bart

AU - Eggert, Angelika

AU - Ellenberg, Jan

AU - Fernández, Xosé M

AU - Figlerowicz, Marek

AU - Gasser, Susan M

AU - Hubner, Norbert

AU - Kjems, Jørgen

AU - Knoblich, Jürgen A

AU - Krabbe, Grietje

AU - Lichter, Peter

AU - Linnarsson, Sten

AU - Marine, Jean-Christophe

AU - Marioni, John C

AU - Marti-Renom, Marc A

AU - Netea, Mihai G

AU - Nickel, Dörthe

AU - Nollmann, Marcelo

AU - Novak, Halina R

AU - Parkinson, Helen

AU - Piccolo, Stefano

AU - Pinheiro, Inês

AU - Pombo, Ana

AU - Popp, Christian

AU - Reik, Wolf

AU - Roman-Roman, Sergio

AU - Rosenstiel, Philip

AU - Schultze, Joachim L

AU - Stegle, Oliver

AU - Tanay, Amos

AU - Testa, Giuseppe

AU - Thanos, Dimitris

AU - Theis, Fabian J

AU - Torres-Padilla, Maria-Elena

AU - Valencia, Alfonso

AU - Vallot, Céline

AU - van Oudenaarden, Alexander

AU - Vidal, Marie

AU - Voet, Thierry

AU - LifeTime Community Working Groups

AU - Kirchhof, Paulus

PY - 2020/11

Y1 - 2020/11

N2 - Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.

AB - Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.

KW - Artificial Intelligence

KW - Cell- and Tissue-Based Therapy

KW - Delivery of Health Care/ethics

KW - Early Diagnosis

KW - Education, Medical

KW - Europe

KW - Female

KW - Health

KW - Humans

KW - Legislation, Medical

KW - Male

KW - Medicine/methods

KW - Pathology

KW - Single-Cell Analysis

U2 - 10.1038/s41586-020-2715-9

DO - 10.1038/s41586-020-2715-9

M3 - SCORING: Journal article

C2 - 32894860

VL - 587

SP - 377

EP - 386

JO - NATURE

JF - NATURE

SN - 0028-0836

IS - 7834

ER -